Patents by Inventor Paul E. Fraser
Paul E. Fraser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11955207Abstract: The disclosure provides systems and methods for data analysis of experimental data. The analysis can include reference data that are not directly generated from the present experiment, which reference data may be values of the experimental parameters that were either provided by a user, computed by the system with input from a user, or computed by the system without using any input from a user. Another example of such reference data may be information about the instrument, such as the calibration method of the instrument.Type: GrantFiled: June 30, 2016Date of Patent: April 9, 2024Assignee: Emerald Cloud Lab, Inc.Inventors: Alex M. Yoshikawa, Anand V. Sastry, Asuka Ota, Ben C. Kline, Bradley M. Bond, Brian M. Frezza, Cameron R. Lamoureux, Catherine L. Hofler, Cheri Y. Li, Courtney E. Webster, Daniel J. Kleinbaum, George N. Stanley, George W. Fraser, Guillaume Robichaud, Hayley E. Buchman, James R. McKernan, Jonathan K. Leung, Paul R. Zurek, Robert M. Teed, Ruben E. Valas, Sean M. Fitzgerald, Sergio I. Villarreal, Shayna L. Hilburg, Shivani S. Baisiwala, Srikant Vaithilingam, Wyatt J. Woodson, Yang Choo, Yidan Y. Cong
-
Publication number: 20120180143Abstract: The present invention provides a transgenic animal model of Alzheimer's Disease designated TgCRND8 as well as a method for making such model, which allows for the characterization of the etiology of the disease as well as for provide a system for the development and testing of potential treatments.Type: ApplicationFiled: December 21, 2011Publication date: July 12, 2012Applicant: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTOInventors: Peter H. St. George-Hyslop, Paul E. Fraser, David Westaway
-
Patent number: 8067224Abstract: Presenilin Associated Membrane Protein (PAMP), and nucleic acids encoding this protein, are provided. PAMP and PAMP nucleic acids provide diagnostic and therapeutic tools for evaluating and treating or preventing neurodegenerative diseases. In a specific embodiment, mutations in PAMP are diagnostic for Alzheimer's Disease or spina bifida. The invention further relates to screening, particularly using high-throughput screens and transgenic animal models, for compounds that modulate the activity of PAMP and presenilins. Such compounds, or gene therapy with PAMP, can be used in treating neurodegenerative diseases, particularly Alzheimer's Disease. In addition, the invention provides PAMP mutants, nucleic acids encoding for PAMP mutants, and transgenic animals expressing PAMP mutants, which in a preferred aspect result in biochemical changes similar to those induced by mutations in ?APP, PS1, or PS2, associated with familial Alzheimer's disease.Type: GrantFiled: September 10, 2008Date of Patent: November 29, 2011Assignee: The Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Paul E. Fraser
-
Publication number: 20110212459Abstract: Presenilin Associated Membrane Protein (PAMP), and nucleic acids encoding this protein, are provided. PAMP and PAMP nucleic acids provide diagnostic and therapeutic tools for evaluating and treating or preventing neurodegenerative diseases. In a specific embodiment, mutations in PAMP are diagnostic for Alzheimer's Disease or spina bifida. The invention further relates to screening, particularly using high-throughput screens and transgenic animal models, for compounds that modulate the activity of PAMP and presenilins. Such compounds, or gene therapy with PAMP, can be used in treating neurodegenerative diseases, particularly Alzheimer's Disease. In addition, the invention provides PAMP mutants, nucleic acids encoding for PAMP mutants, and transgenic animals expressing PAMP mutants, which in a preferred aspect result in biochemical changes similar to those induced by mutations in KNAPP, PS1, or PS2, associated with familial Alzheimer's disease.Type: ApplicationFiled: September 10, 2008Publication date: September 1, 2011Applicant: Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Paul E. Fraser
-
Publication number: 20110076289Abstract: The present invention provides a transgenic animal model of Alzheimer's Disease designated TgCRND8 as well as a method for making such model, which allows for the characterization of the etiology of the disease as well as for provide a system for the development and testing of potential treatments.Type: ApplicationFiled: June 30, 2010Publication date: March 31, 2011Applicant: Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Paul E. Fraser, David Westaway
-
Patent number: 7846679Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.Type: GrantFiled: October 28, 2008Date of Patent: December 7, 2010Assignees: HSC Research and Development Limited Partnership, The Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Patent number: 7838247Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.Type: GrantFiled: August 20, 2007Date of Patent: November 23, 2010Assignees: HSC Research and Development Limited Partnership, The Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Patent number: 7767879Abstract: The present invention provides a transgenic animal model of Alzheimer's Disease designated TgCRND8 as well as a method for making such model, which allows for the characterization of the etiology of the disease as well as for provide a system for the development and testing of potential treatments.Type: GrantFiled: April 7, 2008Date of Patent: August 3, 2010Assignee: The Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Paul E. Fraser, David Westaway
-
Publication number: 20090191650Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.Type: ApplicationFiled: October 28, 2008Publication date: July 30, 2009Applicants: The Governing Council of the University of Toronto, HSC Research and Development Limited PartnershipInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Publication number: 20090087875Abstract: Disclosed is a method for identifying substances that alter the interaction of a presenilin protein with a presenilin-binding protein, including contacting at least the interacting domain of a presenilin protein to a presenilin-binding protein in the presence of a test substance, and measuring the interaction of the presenilin protein and the presenilin-binding protein. Also disclosed is method for identifying substances that modulate the nuclear translocation of an armadillo protein, including providing a culture of cells that express the armadillo protein and a mutant presenilin protein, or a functional fragment thereof that binds an armadillo protein; contacting the culture with a test substance; inducing nuclear translocation of the armadillo protein in the cells; and measuring levels of nuclear armadillo protein as compared to a control as an indication of modulatory activity of the test substance.Type: ApplicationFiled: May 11, 2007Publication date: April 2, 2009Inventors: Peter H. St. George-Hyslop, Paul E. Fraser
-
Patent number: 7507798Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.Type: GrantFiled: February 24, 2005Date of Patent: March 24, 2009Assignees: HSC Research and Development Limited Partnership, The Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Publication number: 20080301827Abstract: The present invention provides a transgenic animal model of Alzheimer's Disease designated TgCRND8 as well as a method for making such model, which allows for the characterization of the etiology of the disease as well as for provide a system for the development and testing of potential treatments.Type: ApplicationFiled: April 7, 2008Publication date: December 4, 2008Applicant: Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Paul E. Fraser, David Westaway
-
Publication number: 20080286813Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.Type: ApplicationFiled: August 20, 2007Publication date: November 20, 2008Inventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Patent number: 7439326Abstract: Presenilin Associated Membrane Protein (PAMP), and nucleic acids encoding this protein, are provided. PAMP and PAMP nucleic acids provide diagnostic and therapeutic tools for evaluating and treating or preventing neurodegenerative diseases. In a specific embodiment, mutations in PAMP are diagnostic for Alzheimer's Disease or spina bifida. The invention further relates to screening, particularly using high-throughput screens and transgenic animal models, for compounds that modulate the activity of PAMP and presenilins. Such compounds, or gene therapy with PAMP, can be used in treating neurodegenerative diseases, particularly Alzheimer's Disease. In addition, the invention provides PAMP mutants, nucleic acids encoding for PAMP mutants, and transgenic animals expressing PAMP mutants, which in a preferred aspect result in biochemical changes similar to those induced by mutations in ?APP, PS1, or PS2, associated with familial Alzheimer's disease.Type: GrantFiled: January 22, 2004Date of Patent: October 21, 2008Assignee: The Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Paul E. Fraser
-
Patent number: 7371920Abstract: The present invention provides a transgenic animal model of Alzheimer's Disease designated TgCRND8 as well as a method for making such model, which allows for the characterization of the etiology of the disease as well as for provide a system for the development and testing of potential treatments.Type: GrantFiled: June 19, 2001Date of Patent: May 13, 2008Assignee: The Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Paul E. Fraser, David Westaway
-
Patent number: 7235383Abstract: Disclosed is a method for identifying substances that alter the interaction of a presenilin protein with a presenilin-binding protein, including contacting at least the interacting domain of a presenilin protein to a presenilin-binding protein in the presence of a test substance, and measuring the interaction of the presenilin protein and the presenilin-binding protein. Also disclosed is method for identifying substances that modulate the nuclear translocation of an armadillo protein, including providing a culture of cells that express the armadillo protein and a mutant presenilin protein, or a functional fragment thereof that binds an armadillo protein; contacting the culture with a test substance; inducing nuclear translocation of the armadillo protein in the cells; and measuring levels of nuclear armadillo protein as compared to a control as an indication of modulatory activity of the test substance.Type: GrantFiled: August 9, 2005Date of Patent: June 26, 2007Assignee: The Governing Council of the University of TorontoInventors: Peter H. St. George-hyslop, Paul E. Fraser
-
Patent number: 6998467Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.Type: GrantFiled: October 12, 2000Date of Patent: February 14, 2006Assignees: The Hospital for Sick Children, HSC Research and Development Limited Partnership, The Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Patent number: 6955896Abstract: Disclosed is a method for identifying substances that alter the interaction of a presenilin protein with a presenilin-binding protein, including contacting at least the interacting domain of a presenilin protein to a presenilin-binding protein in the presence of a test substance, and measuring the interaction of the presenilin protein and the presenilin-binding protein. Also disclosed is method for identifying substances that modulate the nuclear translocation of an armadillo protein, including providing a culture of cells that express the armadillo protein and a mutant presenilin protein, or a functional fragment thereof that binds an armadillo protein; contacting the culture with a test substance; inducing nuclear translocation of the armadillo protein in the cells; and measuring levels of nuclear armadillo protein as compared to a control as an indication of modulatory activity of the test substance.Type: GrantFiled: February 8, 2002Date of Patent: October 18, 2005Assignee: The Governing Council of the Unversity of TorontoInventors: Peter H. St. George-Hyslop, Paul E. Fraser
-
Patent number: 6929919Abstract: Presenilin Associated Membrane Protein (PAMP), and nucleic acids encoding this protein, are provided. PAMP and PAMP nucleic acids provide diagnostic and therapeutic tools for evaluating and treating or preventing neurodevelopmental and neuropsychiatric disorders. In a specific embodiment, mutations in PAMP are diagnostic for schizophrenia. The invention further relates to screening, particularly using high-throughput screens and transgenic animal models, for compounds that modulate the activity of PAMP and presenilins. Such compounds, or gene therapy with PAMP, can be used in treating neurodevelopmental and neuropsychiatric disorders, particularly schizophrenia. In addition, the invention provides PAMP mutants, nucleic acids encoding for PAMP mutants, and transgenic animals expressing PAMP mutants, which in a preferred aspect result in biochemical, morphological, or neuropsychological changes similar to those associated with schizophrenia.Type: GrantFiled: August 31, 2001Date of Patent: August 16, 2005Assignee: The Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Paul E. Fraser
-
Patent number: 6812337Abstract: Presenilin Associated Membrane Protein (PAMP), and nucleic acids encoding this protein, are provided. PAMP and PAMP nucleic acids provide diagnostic and therapeutic tools for evaluating and treating or preventing neurodegenerative diseases. In a specific embodiment, mutations in PAMP are diagnostic for Alzheimer's Disease or spina bifida. The invention further relates to screening, particularly using high-throughput screens and transgenic animal models, for compounds that modulate the activity of PAMP and presenilins. Such compounds, or gene therapy with PAMP, can be used in treating neurodegenerative diseases, particularly Alzheimer's Disease. In addition, the invention provides PAMP mutants, nucleic acids encoding for PAMP mutants, and transgenic animals expressing PAMP mutants, which in a preferred aspect result in biochemical changes similar to those induced by mutations in &bgr;APP, PS1, or PS2, associated with familial Alzheimer's disease.Type: GrantFiled: March 31, 2000Date of Patent: November 2, 2004Assignee: The Governing Council of the University of TorontoInventors: Peter St. George-Hyslop, Paul E. Fraser